What question did this study set out to answer?

The study aims to evaluate the impact of benralizumab on health-related quality of life in patients with hypereosinophilic syndrome.

May 20, 2026American Journal of Respiratory and Critical Care Medicine

C33-19 Health-related Quality of Life Improvements With Benralizumab in Patients With Hypereosinophilic Syndrome: Results From the Phase 3 NATRON Study

View Full Paper

Ask AI

Bookmark

Authors

PAP AkuthotaUniversity of California, San Diego POP O OgboguRainbow Babies & Children's Hospital AKA D KlionNational Institute of Allergy and Infectious Diseases

Discussion

Member takes

Implication

Randomized trial shows benralizumab improves health-related quality of life in hypereosinophilic syndrome, indicating significant benefits for patients.

Key Points

The study aims to evaluate the impact of benralizumab on health-related quality of life in patients with hypereosinophilic syndrome.
Phase 3, randomized, double-blind, multicenter, placebo-controlled trial
Patients received either benralizumab 30 mg Q4W or placebo for 24 weeks
Health-related quality of life was measured using SF-36 version 2
Benralizumab significantly improved scores across all SF-36 subscales by Week 12, with sustained effects until Week 24.
Significant improvements in responder analyses for role limitations (3.31; 1.34, 8.13; p = 0.0092) and general health perceptions (4.12; 1.55, 10.96; p = 0.0046).
Most subscales showed improvements, with the highest least squares mean differences observed in physical functioning (4.40; p = 0.0004) and role limitations (5.02; p = 0.0008).

Cite This Study

Akuthota et al. (2026) studied this question.

synapsesocial.com/papers/6a0d5078f03e14405aa9c4e8 https://doi.org/10.1093/ajrccm/aamag162.278

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows benralizumab improves health-related quality of life in hypereosinophilic syndrome, indicating significant benefits for patients.

C33-19 Health-related Quality of Life Improvements With Benralizumab in Patients With Hypereosinophilic Syndrome: Results From the Phase 3 NATRON Study

Discussion

Member takes

Implication

Key Points

Cite This Study

C33-19 Health-related Quality of Life Improvements With Benralizumab in Patients With Hypereosinophilic Syndrome: Results From the Phase 3 NATRON Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider